Cyteir Therapeutics Inc (CYT)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 09-2005 | 06-2005 | 03-2005 | 12-2004 | 09-2004 | |
| Cash Flows From Operating Activities | |||||
| Net Income | 40,700 | 5,300 | -6,500 | 131,000 | 84,700 |
| Depreciation Amortization | 127,100 | 91,200 | 38,000 | 93,800 | 73,100 |
| Income taxes - deferred | -22,600 | -39,800 | -8,200 | 19,600 | 11,400 |
| Accounts receivable | 6,400 | -20,100 | -5,400 | -24,100 | -40,400 |
| Accounts payable and accrued liabilities | -35,000 | 1,900 | -7,800 | 36,500 | 25,000 |
| Other Working Capital | -31,600 | -52,900 | -89,300 | -72,200 | -82,800 |
| Other Operating Activity | 88,400 | 72,900 | 48,600 | -17,200 | 13,700 |
| Operating Cash Flow | $173,400 | $58,500 | $-30,600 | $167,400 | $84,700 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | -74,700 | -47,500 | -17,100 | -89,300 | -54,300 |
| Net Acquisitions | -1,458,700 | -1,509,000 | -1,501,100 | -4,600 | N/A |
| Other Investing Activity | 177,600 | 101,400 | 1,400 | 9,800 | 9,800 |
| Investing Cash Flow | $-1,355,800 | $-1,455,100 | $-1,516,800 | $-84,100 | $-44,500 |
| Cash Flows From Financing Activities | |||||
| Change In Short Term Borrowing | 467,800 | 521,600 | 581,900 | -9,300 | -1,100 |
| Debt Issued | 874,400 | 864,200 | 725,000 | N/A | N/A |
| Debt Repayment | -292,100 | -186,200 | N/A | N/A | N/A |
| Common Stock Issued | 12,800 | 10,500 | 8,800 | 24,600 | 20,900 |
| Common Stock Repurchased | N/A | N/A | N/A | -13,100 | -13,200 |
| Dividend Paid | -13,200 | -8,600 | -4,000 | -15,700 | -11,700 |
| Other Financing Activity | -5,600 | -5,300 | -5,700 | -7,100 | 2,900 |
| Financing Cash Flow | $1,044,100 | $1,196,200 | $1,306,000 | $-20,600 | $-2,200 |
| Exchange Rate Effect | -7,600 | -9,000 | -5,700 | 10,000 | -4,000 |
| Beginning Cash Position | 323,800 | 323,800 | 323,800 | 251,100 | 251,100 |
| End Cash Position | 177,900 | 114,400 | 76,700 | 323,800 | 285,100 |
| Net Cash Flow | $-145,900 | $-209,400 | $-247,100 | $72,700 | $34,000 |
| Free Cash Flow | |||||
| Operating Cash Flow | 173,400 | 58,500 | -30,600 | 167,400 | 84,700 |
| Capital Expenditure | -74,700 | -47,500 | -17,100 | -89,300 | -54,300 |
| Free Cash Flow | 98,700 | 11,000 | -47,700 | 78,100 | 30,400 |